GRAIL Stock (NASDAQ:GRAL)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$50.65

52W Range

$29.95 - $118.84

50D Avg

$54.91

200D Avg

$66.45

Market Cap

$2.23B

Avg Vol (3M)

$1.27M

Beta

4.64

Div Yield

GRAL Company Profile

GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

1,000

IPO Date

Jun 12, 2024

Website

GRAL Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 25	Dec 24
Non-US	$8.24M	$14.69M
UNITED STATES	$136.76M	-
Americas	-	$108.54M

Fiscal year ends in Dec 25 | Currency in USD

GRAL Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	$147.17M	$125.59M	$93.11M
Operating Income	$-534.16M	$-2.19B	$-1.52B
Net Income	$-408.35M	$-2.03B	$-1.47B
EBITDA	$-377.82M	$-610.17M	$-638.22M
Basic EPS	$-11.11	$-63.54	$-47.20
Diluted EPS	$-11.11	$-63.54	$-47.20

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 25Feb 19, 26 | 5:00 PM

Q3 25Nov 12, 25 | 4:30 PM

Q2 25Aug 12, 25 | 4:30 PM

Peer Comparison

Ticker	Company
IDYA	IDEAYA Biosciences, Inc.
AAPG	Ascentage Pharma Group International
NVST	Envista Holdings Corp
RARE	Ultragenyx Pharmaceutical Inc.
SLNO	Soleno Therapeutics, Inc.
CELC	Celcuity Inc.
XENE	Xenon Pharmaceuticals Inc.
DYN	Dyne Therapeutics, Inc.
CNTA	Centessa Pharmaceuticals plc
APGE	Apogee Therapeutics, Inc.